WO2016139331A1 - Méthodes et compositions pharmaceutiques destinées au traitement du mélanome - Google Patents

Méthodes et compositions pharmaceutiques destinées au traitement du mélanome Download PDF

Info

Publication number
WO2016139331A1
WO2016139331A1 PCT/EP2016/054615 EP2016054615W WO2016139331A1 WO 2016139331 A1 WO2016139331 A1 WO 2016139331A1 EP 2016054615 W EP2016054615 W EP 2016054615W WO 2016139331 A1 WO2016139331 A1 WO 2016139331A1
Authority
WO
WIPO (PCT)
Prior art keywords
melanoma
ivermectin
pak
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/054615
Other languages
English (en)
Inventor
Anne-Françoise TILKIN-MARIAME
Franck GALLARDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovirtech
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Toulouse
Original Assignee
Neovirtech
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovirtech, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Toulouse III Paul Sabatier filed Critical Neovirtech
Publication of WO2016139331A1 publication Critical patent/WO2016139331A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to methods and pharmaceutical compositions for the treatment of melanoma.
  • Melanoma is the most aggressive skin cancer. It often induces metastasis and its incidence is rapidly growing and continues to rise alarmingly. Surgery is curative in nearly all cases before metastatic stage, but when metastasis appears, surgery, radiotherapy and conventional chemotherapy have little curative effects and patient survival is usually short. Molecular alterations are frequent in melanomas. Activating mutations in the serine/threonine kinase BRAF and in particular the BRAFV600E mutation occurs in about 50% of melanomas (Genotyping of cutaneous melanoma. I C Glitza and M A Davies. Chin Clin Oncol. 2014, vol 3 p27- doi:10.3978/j.issn.2304-3865.2014.03.01).
  • This BRAF mutation induces activation of the MAPK pathway, which is involved in essential cellular processes such as proliferation, differentiation and especially invasion, suggesting a relationship between BRAF mutation and metastatic potential (Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Mehnert JM, Kluger HM. Curr Oncol Rep. 2012, vol 14: p 449-457). Therefore several promising new therapies have been developed essentially based on targeted chemotherapy using inhibitors of MAPK pathway and in particular specific anti-BRAFV600E inhibitors: Vemurafenib (PLX4032) and Dabrafenib.
  • Vemurafenib and Dabrafenib block the mutated BRAF protein, inducing cell growth arrest and cell death in tumors carrying this mutation.
  • Clinical trials of Vemurafenib and Dabrafenib have shown therapeutic effect in more than 50% of patients with BRAFV600E positive metastatic melanomas. However, only patients with this mutation benefit from these treatments. In the clinical context, the majority of patients first respond to these inhibitors and most of their metastases regress (Overcoming resistance to BRAF inhibition in BRAF -mutated metastatic melanoma. Francesco Spagnolo,Paola Ghiorzo and Paola Queirolo. Oncotarget, 2014, Vol. 5, No. 21 pl02-21).
  • Novel immunotherapies using antibodies targeting inhibitor components of immune responses such as: anti-CTLA-4 (Ipilimumab) or anti-PD-1 (Nivolumab (BMS-936558) and Pembrolizumab) are also promising but occasionally cause dangerous side effects resulting from autoimmune reactions. Reliable treatments of metastatic melanoma are not yet available and the exploration of new chemotherapies or immunotherapies is still needed.
  • the inventors searched for molecules with differential toxicity on normal cells and metastatic melanoma cells and in particular for molecules that could be able to reduce the development of metastases and potentiate the anti-melanoma effect of Vemurafenib and Dabrafenib.
  • the present invention relates to methods and pharmaceutical compositions for the treatment of melanoma.
  • the role of macrocyclic lactones in melanoma was investigated by the inventors using human melanoma cell lines, murine melanoma cell lines, melanoma treatments with Vemurafenib and Dabrafenib, NMRI-nu/nu mice and C57BL/6-IFN-y KO mice developing melanoma metastasis.
  • Ivermectin induce sensitization of melanoma cells to treatments with inhibitors of BRAFV600E such as Vemurafenib and Dabrafenib.
  • BRAFV600E such as Vemurafenib and Dabrafenib.
  • the inventors demonstrated that low doses of Ivermectin (corresponding to 1/5 or 1/10 of its IC50) potentiate the action of Vemurafenib on melanoma cells that do not carry the BRAFV600E mutation, and which are normally insensitive to Vemurafenib cytotoxicity. Therefore, a treatment protocol combining Vemurafenib with Ivermectin is expected to be efficient for all metastatic melanoma patients. Furthermore this low dose of Ivermectin also potentiates the action of Dabrafenib on melanoma cells.
  • PAK1 is the Ivermectin target involved in melanoma treatment sensitivity.
  • concentrations used by the inventors in the in vivo experiments are low (3,25mg/kg), corresponding to the doses used in anti parasitic treatments in humans, contrary to what had been previously shown with colorectal cancers (10, 50mg and even lOOmg/kg/day) (WO 2012150543 Al).
  • the present invention relates to a compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment for use in the prevention or treatment of melanoma in a subject in need thereof.
  • a subject denotes a mammal.
  • a subject according to the invention refers to any subject (preferably human) afflicted with or susceptible to be afflicted with a cancer.
  • a subject according to the invention is a subject afflicted or susceptible to be afflicted with melanoma or melanoma metastasis.
  • melanoma has its general meaning in the art and refers to melanoma such as revised in the World Health Organisation Classification C43-C44.
  • the term “melanoma” further encompasses both primary and metastatic melanoma.
  • the term “melanoma” also relates to melanoma and metastatic melanoma with or without BRAF mutations including but not limiting to mutations such as BRAF V600E mutation.
  • the term "melanoma treatment” has its general meaning in the art and refers to chemotherapy, immunotherapy, radiotherapy or targeted chemotherapy with therapeutic active agents used in the treatment of melanoma or metastatic melanoma.
  • the melanoma treatment is selected from the group consisting of but not limited to BRAF inhibitors such as Vemurafenib (PLX4032), Dabrafenib (GSK2118436), Raf-1 inhibitor such as Sorafenib, MEK inhibitors such as Trametinib, Selumetini, and MAPK pathway inhibitors such as described in (Dossett LA, Kudchadkar R , Zager JS. BRAF and MEK inhibition in melanoma.
  • BRAF inhibitors such as Vemurafenib (PLX4032), Dabrafenib (GSK2118436), Raf-1 inhibitor such as Sorafenib, MEK inhibitors such as Trametinib, Selumetini, and MAPK pathway inhibitors such
  • PAK-1 has its general meaning in the art and refers to P21- Activated Kinase 1, also known as Serine/threonine-protein kinase PAK 1, or P21 protein (Cdc42/Rac)-activated kinase 1.
  • PAK-1 is a member of p21 -activated kinases family (PAKs) involved in the ERK activation, MAPK pathway activation and that are critical effectors that link the Rho GTPases to cytoskeleton reorganization and nuclear signaling and have been implicated in a wide range of biological activities.
  • PAKs p21 -activated kinases family
  • PAK-1 proteins Several functions have been attributed to PAK-1 proteins, including roles in cell transformation, cell motility and morphology, tumor growth, and tumorigenesis (Hisashi Hashimoto et al. Drug Discov Ther. 2009; 3(6):243-246; Ong et al, 2013).
  • a gene product can be the direct transcriptional product of a gene (e.g. , mRNA, tRNA, rRNA, antisense RNA, ribozyme, structural RNA or any other type of RNA) or a protein produced by translation of a mRNA.
  • Gene products also include messenger RNAs, which are modified, by processes such as capping, polyadenylation, methylation, and editing, and proteins (e.g., PAK-1) modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, SUMOylation, ADP-ribosylation, myristilation, and glycosylation.
  • proteins e.g., PAK-1 modified by, for example, methylation, acetylation, phosphorylation, ubiquitination, SUMOylation, ADP-ribosylation, myristilation, and glycosylation.
  • an “inhibitor of expression” refers to a natural or synthetic compound that has a biological effect to inhibit the expression of a gene such as pharmaceutical compounds or targeted siRNA).
  • PAK-1 antagonist refers to a compound that selectively blocks or inactivates PAK-1.
  • selectively blocks or inactivates refers to a compound that preferentially binds to and blocks or inactivates PAK-1 with a greater affinity and potency, respectively, than its interaction with the other sub-types or isoforms of the PAKs family.
  • Compounds that prefer PAK-1, but that may also block or inactivate other PAKs, as partial or full antagonists, are contemplated.
  • the "PAK-1 antagonist” refers to compounds that blocks PAK-1 interaction with proteins involved in ERK pathway and MAPK pathway such as RAF- 1 (CRAF), inhibits its phosphorylation, and blocks MAPK cascade.
  • RAF- 1 CRAF
  • a PAK-1 antagonist is a small organic molecule, a peptide, a polypeptide, an aptamer or an intra- antibody.
  • PAK-1 antagonist is a macrocyclic lactone.
  • macrocyclic lactones has its general meaning in the art and refers to macrocyclic lactones and macrocyclic lactones derivatives described in (Lespine A. Lipid-like properties and pharmacology of the anthelmintic macrocyclic lactones. Expert Opin Drug Metab Toxicol. 2013 Dec; 9(12): 1581-95).
  • macrocyclic lactones also refers to macrocyclic lactones and macrocyclic lactones derivatives described in WO 2012/078605, WO 2012/150543, WO 2011/075592, WO 93/16189, WO 2012/028556 and US 3,503,994.
  • macrocyclic lactones has its general meaning in the art and refers to compounds described in Lespine A. 2013 such as compounds having the formula:
  • macrocyclic lactones include but are not limited to Ivermectin (Stromectol), Doramectin, Selamectin, Moxidectin, Milbemycin, Abamectin, Nemadectin and Eprinomectin.
  • the present invention also relates to a macrocyclic lactone in combination with one or more melanoma treatment for use in the prevention or treatment of melanoma in a subject in need thereof.
  • the present invention relates to a macrocyclic lactone such as Ivermectin, Doramectin, Selamectin, Moxydectin or Abamectin in combination with one or more melanoma treatment such as Vemurafenib or Dabrafenib for use in the prevention or treatment of melanoma in a subject in need thereof.
  • a macrocyclic lactone such as Ivermectin, Doramectin, Selamectin, Moxydectin or Abamectin
  • the present invention relates to Ivermectin in combination with Vemurafenib and/or Dabrafenib for use in the prevention or treatment of melanoma in a subject in need thereof.
  • the PAK-1 antagonist of the invention is an aptamer.
  • Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity.
  • Such ligands may be isolated through Systematic Evolution of Ligands by Exponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., 1990.
  • the random sequence library is obtainable by combinatorial chemical synthesis of DNA.
  • each member is a linear oligomer, eventually chemically modified, of a unique sequence.
  • Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S.D., 1999.
  • Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as E. coli Thioredoxin A that are selected from combinatorial libraries by two hybrid methods (Colas et al., 1996). Then after raising aptamers directed against PAK- 1 of the invention as above described, the skilled man in the art can easily select those inhibiting PAK-1.
  • the compound of the invention is an inhibitor of PAK-1 expression.
  • Inhibitors of PAK-1 expression for use in the present invention may be based on antisense oligonucleotide constructs.
  • Anti-sense oligonucleotides, including anti-sense R A molecules and anti-sense DNA molecules, would act to directly block the translation of PAK- 1 mRNA by binding thereto and thus preventing protein translation or increasing mRNA degradation, thus decreasing the level of PAK-1 proteins, and thus activity, in a cell.
  • antisense oligonucleotides of at least about 15 bases and complementary to unique regions of the mRNA transcript sequence encoding PAK-1 can be synthesized, e.g., by conventional phosphodiester techniques and administered by e.g., intravenous injection or infusion.
  • Methods for using antisense techniques for specifically alleviating gene expression of genes whose sequence is known are well known in the art (e.g. see U.S. Pat. Nos. 6,566,135; 6,566,131; 6,365,354; 6,410,323; 6,107,091; 6,046,321; and 5,981,732).
  • Small inhibitory RNAs can also function as inhibitors of PAK-1 expression for use in the present invention.
  • PAK-1 gene expression can be reduced by contacting the subject or cell with a small double stranded RNA (dsRNA), or a vector or construct causing the production of a small double stranded RNA, such that PAK-1 expression is specifically inhibited (i.e. RNA interference or RNAi).
  • dsRNA small double stranded RNA
  • RNAi RNA interference
  • Methods for selecting an appropriate dsRNA or dsRNA-encoding vector are well known in the art for genes whose sequence is known (e.g. see Tuschl, T. et al. (1999); Elbashir, S. M. et al. (2001); Hannon, GJ. (2002); McManus, MT.
  • Ribozymes can also function as inhibitors of PAK-1 expression for use in the present invention.
  • Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
  • the mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage.
  • Engineered hairpin or hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of PAK-1 mRNA sequences are thereby useful within the scope of the present invention.
  • ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, which typically include the following sequences, GUA, GUU, and GUC. Once identified, short RNA sequences of between about 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site can be evaluated for predicted structural features, such as secondary structure, that can render the oligonucleotide sequence unsuitable. The suitability of candidate targets can also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using, e.g., ribonuclease protection assays.
  • antisense oligonucleotides and ribozymes useful as inhibitors of PAK-1 expression can be prepared by known methods. These include techniques for chemical synthesis such as, e.g., by solid phase phosphoramadite chemical synthesis. Alternatively, anti-sense RNA molecules can be generated by in vitro or in vivo transcription of DNA sequences encoding the RNA molecule. Such DNA sequences can be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Various modifications to the oligonucleotides of the invention can be introduced as a means of increasing intracellular stability and half-life.
  • Possible modifications include but are not limited to the addition of flanking sequences of ribonucleotides or deoxyribonucleotides to the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2'-0-methyl rather than phosphodiesterase linkages within the oligonucleotide backbone.
  • Antisense oligonucleotides siRNAs and ribozymes of the invention may be delivered in vivo alone or in association with a vector.
  • a "vector" is any vehicle capable of facilitating the transfer of the antisense oligonucleotide siRNA or ribozyme nucleic acid to the cells and preferably cells expressing PAK-1.
  • the vector transports the nucleic acid to cells with reduced degradation relative to the extent of degradation that would result in the absence of the vector.
  • the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antisense oligonucleotide siRNA or ribozyme nucleic acid sequences.
  • Viral vectors are a preferred type of vector and include, but are not limited to nucleic acid sequences from the following viruses: retrovirus, such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA virus such as a retrovirus.
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus
  • retrovirus such as moloney murine leukemia virus, harvey murine sarcoma virus, murine mammary tumor virus, and rouse sarcoma virus
  • adenovirus adeno
  • Non-cytopathic viruses include retroviruses (e.g., lentivirus), the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes in vivo.
  • adeno-viruses and adeno-associated viruses are double-stranded DNA viruses that have already been approved for human use in gene therapy.
  • the adeno-associated virus can be engineered to be replication deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions.
  • the adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression characteristic of retroviral infection.
  • adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event.
  • the adeno-associated virus can also function in an extrachromosomal fashion.
  • Plasmid vectors have been extensively described in the art and are well known to those of skill in the art. See e.g., SANBROOK et al., "Molecular Cloning: A Laboratory Manual," Second Edition, Cold Spring Harbor Laboratory Press, 1989.
  • plasmid vectors have been used as DNA vaccines for delivering antigen- encoding genes to cells in vivo. They are particularly advantageous for this because they do not have the same safety concerns as with many of the viral vectors.
  • These plasmids however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.
  • Plasmids may be delivered by a variety of parenteral, mucosal and topical routes.
  • the DNA plasmid can be injected by intramuscular, intradermal, subcutaneous, or other routes. It may also be administered by intranasal sprays or drops, rectal suppository and orally.
  • the plasmids may be given in an aqueous solution, dried onto gold particles or in association with another DNA delivery system including but not limited to liposomes, dendrimers, cochleate and microencapsulation.
  • a further aspect of the present invention relates to the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment for use in the prevention of melanoma metastasis in a subject in need thereof.
  • the present invention relates to the macrocyclic lactone in combination with one or more melanoma treatment for use in the prevention of melanoma metastasis in a subject in need thereof.
  • the present invention relates to the macrocyclic lactone such as Ivermectin, Doramectin, Selamectin, Moxydectin or Abamectin in combination with one or more melanoma treatment such as Vemurafenib or Dabrafenib for use in the prevention of melanoma metastasis in a subject in need thereof.
  • macrocyclic lactone such as Ivermectin, Doramectin, Selamectin, Moxydectin or Abamectin
  • the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors of the invention sensitizes melanoma cells to melanoma treatment.
  • the present invention relates to the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors for use in a method for enhancing therapeutic efficacy of melanoma treatment in a subject in need thereof.
  • the present invention relates to the macrocyclic lactone according to the invention for use in a method for enhancing therapeutic efficacy of melanoma treatment in a subject in need thereof.
  • the present invention relates to the macrocyclic lactone such as
  • Ivermectin, Doramectin, Selamectin, Moxydectin or Abamectin for use in a method for enhancing therapeutic efficacy of melanoma treatment such as Vemurafenib or Dabrafenib in a subject in need thereof.
  • the present invention relates to Ivermectin for use in a method for enhancing therapeutic efficacy of Vemurafenib and/or Dabrafenib in a subject in need thereof.
  • the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors of the present invention and the melanoma treatment as described above are administered to the subject in a therapeutically effective amount.
  • a “therapeutically effective amount” of the compound of the present invention as above described is meant a sufficient amount of the compound. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidential with the specific compound employed; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the compound of the present invention for the symptomatic adjustment of the dosage to the subject to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the compound of the present invention, preferably from 1 mg to about 100 mg of the compound of the present invention.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • the compound selected from the group consisting of PAK- 1 antagonists or PAK-1 expression inhibitors according to the invention may be used in low doses.
  • the term “low doses” refers to macrocyclic lactones concentration (such as Ivermectin) between 0.01 ⁇ and 20 ⁇ .
  • the term “low doses” refers to macrocyclic lactones concentration of 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 ⁇ .
  • the term “low doses” refers to macrocyclic lactones concentrations from 1/10 to 1/3 of their IC50, particularly, from 1/10 to 1/5 of their IC50.
  • the therapeutically effective amount of the melanoma treatment of the invention is well known in the art.
  • the therapeutically effective amount of the melanoma treatment relates to melanoma treatment concentration (such as Vemurafenib or Dabrafenib) between 0.01 ⁇ to 6 ⁇ .
  • the therapeutically effective amount of the melanoma treatment relates to melanoma treatment concentration of 0.01, 0.05, 0.1, 0.5, 1.0, 1.5, 2, 3, 4, 5, 6 ⁇ , IC50 from 0,5 to 4,5 ⁇ .
  • the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors of the invention is administered sequentially or concomitantly with one or more melanoma treatment.
  • chemotherapeutic agent refers to chemical compounds that are effective in inhibiting tumor growth.
  • chemotherapeutic agents include alkylating agents such as dacarbazine, thiotepa and cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaorarnide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a carnptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolast
  • calicheamicin especially calicheamicin (11 and calicheamicin 211, see, e.g., Agnew Chem Intl. Ed. Engl. 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, canninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolin
  • paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.].) and doxetaxel (TAXOTERE®, Rhone -Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6- thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP- 16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-1 1 ; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and phannaceutically acceptable salts, acids or derivatives of any of the above.
  • antihormonal agents that act to regulate or inhibit honnone action on tumors
  • anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and phannaceutically acceptable salts, acids or derivatives of any of the above.
  • the therapeutic active agent is a targeted cancer therapy.
  • Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer.
  • Targeted cancer therapies are sometimes called “molecularly targeted drugs", “molecularly targeted therapies”, “precision medicines”, or similar names.
  • the targeted therapy consists of administering the subject with a tyrosine kinase inhibitor as defined above.
  • therapeutic active agent is an immunotherapeutic agent.
  • immunotherapeutic agent refers to a compound, composition or treatment that indirectly or directly enhances, stimulates or increases the body's immune response against cancer cells and/or that decreases the side effects of other anticancer therapies. Immunotherapy is thus a therapy that directly or indirectly stimulates or enhances the immune system's responses to cancer cells and/or lessens the side effects that may have been caused by other anti-cancer agents. Immunotherapy is also referred to in the art as immunologic therapy, biological therapy biological response modifier therapy and biotherapy. Examples of common immunotherapeutic agents known in the art include, but are not limited to, cytokines, cancer vaccines, monoclonal antibodies and non-cytokine adjuvants.
  • the immunotherapeutic treatment may consist of administering the subject with an amount of immune cells (T cells, NEC, cells, dendritic cells, B cells).
  • Immunotherapeutic agents can be non-specific, i.e. boost the immune system generally so that the human body becomes more effective in fighting the growth and/or spread of cancer cells, or they can be specific, i.e. targeted to the cancer cells themselves immunotherapy regimens may combine the use of nonspecific and specific immunotherapeutic agents.
  • Non-specific immunotherapeutic agents are substances that stimulate or indirectly improve the immune system.
  • Non-specific immunotherapeutic agents have been used alone as a main therapy for the treatment of cancer, as well as in addition to a main therapy, in which case the non-specific immunotherapeutic agent functions as an adjuvant to enhance the effectiveness of other therapies (e.g. cancer vaccines).
  • Non-specific immunotherapeutic agents can also function in this latter context to reduce the side effects of other therapies, for example, bone marrow suppression induced by certain chemotherapeutic agents.
  • Non-specific immunotherapeutic agents can act on key immune system cells and cause secondary responses, such as increased production of cytokines and immunoglobulins. Alternatively, the agents can themselves comprise cytokines.
  • Nonspecific immunotherapeutic agents are generally classified as cytokines or non-cytokine adjuvants.
  • cytokines have found application in the treatment of cancer either as general non-specific immunotherapies designed to boost the immune system, or as adjuvants provided with other therapies. Suitable cytokines include, but are not limited to, interferons, interleukins and colony-stimulating factors. Interferons (IFNs) contemplated by the present invention include the common types of IFNs, IFN-alpha (IFN-a), IETNf-beta (IFN- ⁇ ) and IFN- gamma (IFN- ⁇ ). IFNs can act directly on cancer cells, for example, by slowing their growth, promoting their development into cells with more normal behaviour and/or increasing their production of antigens thus making the cancer cells easier for the immune system to recognise and destroy.
  • IFNs Interferons
  • IFN-a IFN-alpha
  • IFN- ⁇ IFN- ⁇
  • IFN- ⁇ IFN-gamma
  • IFNs can also act indirectly on cancer cells, for example, by slowing down angiogenesis, boosting the immune system and/or stimulating natural killer (NEC) cells, T cells and macrophages.
  • Recombinant IFN-alpha is available commercially as Roferon (Roche Pharmaceuticals) and Intron A (Schering Corporation).
  • Interleukins contemplated by the present invention include IL-2, IL-4, IL-11 and IL-12. Examples of commercially available recombinant interleukins include Proleukin® (IL-2; Chiron Corporation) and Neumega® (IL- 12; Wyeth Pharmaceuticals). Zymogenetics, Inc.
  • Colony-stimulating factors contemplated by the present invention include granulocyte colony stimulating factor (G-CSF or filgrastim), granulocyte-macrophage colony stimulating factor (GM-CSF or sargramostim) and erythropoietin (epoetin alfa, darbepoietin). Treatment with one or more growth factors can help to stimulate the generation of new blood cells in subjects undergoing traditional chemotherapy.
  • CSFs can be helpful in decreasing the side effects associated with chemotherapy and can allow for higher doses of chemotherapeutic agents to be used.
  • Various-recombinant colony stimulating factors are available commercially, for example, Neupogen® (G-CSF; Amgen), Neulasta (pelfilgrastim; Amgen), Leukine (GM-CSF; Berlex), Procrit (erythropoietin; Ortho Biotech), Epogen (erythropoietin; Amgen), Arnesp (erytropoietin).
  • immunotherapeutic agents can be active, i.e. stimulate the body's own immune response, or they can be passive, i.e.
  • Passive specific immunotherapy typically involves the use of one or more monoclonal antibodies that are specific for a particular antigen found on the surface of a cancer cell or that are specific for a particular cell growth factor.
  • Monoclonal antibodies may be used in the treatment of cancer in a number of ways, for example, to enhance a subject's immune response to a specific type of cancer, to interfere with the growth of cancer cells by targeting specific cell growth factors, such as those involved in angiogenesis, or by enhancing the delivery of other anticancer agents to cancer cells when linked or conjugated to agents such as chemotherapeutic agents, radioactive particles or toxins.
  • Monoclonal antibodies currently used as cancer immunotherapeutic agents that are suitable for inclusion in the combinations of the present invention include, but are not limited to, rituximab (Rituxan®), trastuzumab (Herceptin®), ibritumomab tiuxetan (Zevalin®), tositumomab (Bexxar®), cetuximab (C-225, Erbitux®), bevacizumab (Avastin®), gemtuzumab ozogamicin (Mylotarg®), alemtuzumab (Campath®), and BL22.
  • Other examples include anti-CTLA4 antibodies (e.g.
  • antibodies include B cell depleting antibodies.
  • Typical B cell depleting antibodies include but are not limited to anti-CD20 monoclonal antibodies [e.g.
  • the immunotherapeutic treatment may consist of allografting, in particular, allograft with hematopoietic stem cell HSC.
  • the immunotherapeutic treatment may also consist in an adoptive immunotherapy as described by Nicholas P. Restifo, Mark E.
  • NK cells circulating lymphocytes
  • the activated lymphocytes or NK cells are most preferably be the subject's own cells that were earlier isolated from a blood or tumor sample and activated (or "expanded") in vitro.
  • the therapeutic active agent is a radiotherapeutic agent.
  • radiotherapeutic agent as used herein, is intended to refer to any radiotherapeutic agent known to one of skill in the art to be effective to treat or ameliorate cancer, without limitation.
  • the radiotherapeutic agent can be an agent such as those administered in brachytherapy or radionuclide therapy.
  • Such methods can optionally further comprise the administration of one or more additional cancer therapies, such as, but not limited to, chemotherapies, and/or another radiotherapy.
  • the present invention also relates to a method for preventing or treating melanoma in a subject in need thereof, comprising the step of administering to said subject the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment.
  • the present invention also relates to a method for preventing melanoma metastasis in a subject in need thereof, comprising the step of administering to said subject the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment.
  • the present invention also relates to a method for enhancing therapeutic efficacy of melanoma treatment in a subject in need thereof, comprising the step of administering to said subject the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors.
  • Pharmaceutical composition and kits of the invention are provided.
  • the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment of the invention may be used or prepared in a pharmaceutical composition.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment of the invention and a pharmaceutical acceptable carrier for use in the prevention or treatment of melanoma in a subject in need thereof.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment of the invention and a pharmaceutical acceptable carrier for use in the prevention of melanoma metastasis in a subject in need thereof.
  • the invention relates to a pharmaceutical composition comprising the compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors of the invention and a pharmaceutical acceptable carrier for use in a method for enhancing therapeutic efficacy of melanoma treatment in a subject in need thereof.
  • the compounds of the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions.
  • “Pharmaceutically” or “pharmaceutically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human, as appropriate.
  • a pharmaceutically acceptable carrier or excipient refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • the active principle in the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, transdermal, local or rectal administration, can be administered in a unit administration form, as a mixture with conventional pharmaceutical supports, to human beings.
  • Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
  • the pharmaceutical compositions contain vehicles, which are pharmaceutically acceptable for a formulation capable of being injected.
  • vehicles which are pharmaceutically acceptable for a formulation capable of being injected.
  • These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and the like or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Solutions comprising compounds of the invention as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the compounds of the invention can be formulated into a composition in a neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with several of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media which can be employed, will be known to those of skill in the art in light of the present disclosure. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • other pharmaceutically acceptable forms include, e.g. tablets or other solids for oral administration; liposomal formulations; time-release capsules; and any other form currently used.
  • said compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors of the invention and melanoma treatments are contained in the same composition or administrated separately for simultaneous, separate or sequential use in the prevention or treatment of melanoma.
  • kits comprising at least one compound selected from the group consisting of PAK-1 antagonists or PAK-1 expression inhibitors in combination with one or more melanoma treatment of the invention.
  • Kits containing the compounds of the invention find use in therapeutic methods.
  • the present invention relates to a method of screening a candidate compound for use as a drug for the prevention or treatment of melanoma in a subject in need thereof, wherein the method comprises the steps of: i) providing candidate compounds and ii) selecting candidate compounds that blocks the action of PAK-1.
  • the present invention also relates to the candidate compound according to the invention in combination with one or more melanoma treatment for use in the prevention or treatment of melanoma in a subject in need thereof.
  • the present invention relates to a method of screening a candidate compound for use as a drug for the prevention or treatment of melanoma in a subject in need thereof, wherein the method comprises the steps of:
  • a candidate compound such as small organic molecule, intra-antibodies, peptide or polypeptide
  • measuring the activity of the PAK- 1 involves determining ERK and MAPK pathway activation on the PAK-1 cloned and transfected in a stable manner into a CHO cell line or measuring RAF-1 phosphorylation in the presence or absence of the candidate compound (Hisashi Hashimoto et al. Drug Discov Ther. 2009; 3(6):243-246; Ong et al, 2013).
  • Tests and assays for screening and determining whether a candidate compound is a PAK-1 antagonist are well known in the art. In vitro and in vivo assays may be used to assess the potency and selectivity of the candidate compounds to reduce PAK-1 activity.
  • Activities of the candidate compounds, their ability to bind PAK-1 and their ability to inhibit PAK-1 activity may be tested using isolated melanoma cells expressing PAK-1, CHO cell line cloned and transfected in a stable manner by the human PAK-1.
  • Cells expressing another PAKs than PAK-1 may be used to assess selectivity of the candidate compounds.
  • FIGURES are a diagrammatic representation of FIGURES.
  • FIG. 1 Ivermectin is cytotoxic against LB39-MEL cells but not on normal human fibroblast.
  • the human melanoma cells LB39-MEL and human normal fibroblasts MRC5 (ATCC
  • CCL171) were seeded at lxl 0 4 cells/well and treated with vehicle alone (RPMI/DMSO 0,5%) or with Ivermectin at 5 ⁇ for 72h. Number of cells after treatment was quantified using a Cellomics Arrayscan microscope.
  • Figure 2 Pictures illustrating Ivermectin cytotoxicity on LB39-MEL cells
  • LB 1319-MEL wild type NRAS and BRAF
  • WM266- 4 wild type NRAS and mutated BRAFV600E
  • BB74-MEL wild type NRAS and mutated BRAFV600E
  • LB1829-MEL MZ2-MEL.3 (BRAF-wt and NRAS Q61K)
  • LB583-MEL LB1757-MEL and LB33-MEL
  • B16F10 wild type NRAS and BRAF
  • mice Twenty two C57B1/6 IFNy-KO mice were weighed before and after intraperitoneal (IP) injections. Before injections, the average weight of mice was 18,2 grams (left), the group was then split in two groups that received one intraperitoneal injection/day for 7 days of 0,1 mL of vehicle alone (PBS/DMSO 0,25%) or vehicle with Ivermectin at 3,25 mg/kg. After vehicle injections the average weight of mice was 18,3 g (middle). After Ivermectin injections the average weight of mice was 16,7 g (right).
  • IP intraperitoneal
  • mice were weighed before and after intraperitoneal injections. Before injections the average weight of mice was 25,8 grams (left), the group was then split in two groups that received one intraperitoneal injection/day for 20 days of 0,1 mL of vehicle alone (PBS/DMSO 0,25%) or vehicule with Ivermectin at 3,25 mg/kg. After vehicle injection, the average weight of mice was 27,7 grams (middle). After Ivermectin injections, the average weight of mice was 26,7 grams (right).
  • FIG. 6 Intraperitoneal Ivermectin injections decrease lung metastases implantation of B16F10 murine melanoma cells in C57BL/6 IFNy-KO mice
  • B16F10 cells (lxlO 5 cells/mouse) were injected intravenously in the tail vein of twenty C57BL/6 IFNy-KO mice and left untreated for 48h. Then mice were subsequently treated by intraperitoneal injections lx/day for 7 days with 0,1 mL of vehicle alone (PBS/DMSO 0,25%) or with 3.25mg/kg of Ivermectin. Mice were sacrificed at Day 10, their lungs were removed and the number of metastasis counted in double blind experiments. Number of metastases/mouse is represented in vehicle treated condition (average at 79) on the left and Ivermectin treated conditions (average at 41) on the right.
  • FIG. 7 Intraperitoneal Ivermectin injections decrease lung metastases implantation of WM266-4 human melanoma cells in Nude mice
  • WM266-4 cells (lxl 0 6 cells/mouse) were injected intravenously in the tail vein of thirteen NMRI nu/nu mice and left untreated for 48h. Then mice were subsequently treated by intraperitoneal injection lx/day for 17 days with 0,1 mL of vehicle alone (PBS/DMSO 0,25%) or with 3.25mg/kg of Ivermectin. Mice were sacrificed at Day 20, their lungs were removed and the number of metastasis was detected using immunohistochemical staining with KB A.62 mAb and counted in double blind experiments. Number of metastases/mouse is represented in vehicle treated condition on the left and Ivermectin treated condition on the right.
  • Figure 8 Macrocyclic lactones cytotoxicity on BRAF-wt melanoma cells
  • LB1319-MEL cells were seeded at 5xl0 3 cells/well and treated with increasing concentration of Ivermectin, Doramectin, Selamectin, Moxidectin, or Abamectin. After 72h of treatment, cell number was quantified using a Cellomics Arrayscan microscope. Number of cells in the vehicle treated condition was used to normalize results.
  • Figure 9 Macrocyclic lactones cytotoxicity on BRAFV600E mutated melanoma cells
  • WM266-4 cells were seeded at 5xl0 3 cells/well and treated with increasing concentration of Ivermectin, Doramectin, Selamectin, Moxidectin, or Abamectin. After 72h of treatment, cell number was quantified using a Cellomics Arrayscan microscope. Number of cells in the vehicle treated condition was used to normalize results.
  • WM266-4 cells were treated with increasing concentrations of Ivermectin alone (0,37; 1; 3 and 10 ⁇ ), or with increasing concentrations of PLX-4032 alone (0,07; 0,22; 0,66 and 2) or with a fixed concentration of Ivermectin (0,37 ⁇ ) plus increasing concentrations of PLX4032 (0,07; 0,22; 0,66 and 2). After 72h of treatment, cell number was quantified using a Cellomics Arrayscan microscope. Number of cells in the untreated condition was used to normalize results.
  • Figure 11 Combination of a low dose of Ivermectin with increasing doses of Vemurafenib do not enhance its cytotoxicity against WM266-4 mutated melanoma cells
  • WM266- 4 cells were treated with increasing concentrations of Ivermectin alone (0,37; 1; 3 and 10 ⁇ ), or with increasing concentrations of PLX-4032 alone (0,07; 0,22; 0,66 and 2) or with a fixed concentration of Ivermectin (0,37 ⁇ ) plus increasing concentrations of PLX4032 (0,07; 0,22; 0,66 and 2). Surviving cells were counted after 72h incubation using a Cell Counter.
  • Figure 12 Low doses of Ivermectin, Moxidectin or Abamectin do not potentiate Vemurafenib activity on BRAFV600E mutated melanoma cells
  • Ivermectin (I), Moxidectin (M) and Abamectin (A) plus Vemurafenib (V) combinations on the survival of BRAFV600E mutated melanoma cells.
  • WM266-4 cells were treated with a fixed concentration of Vemurafenib (0,66 ⁇ ) alone or with combinations of fixed concentrations (0,37 ⁇ ) of Ivermectin (10,3), Moxidetin (M0,3) or Abamectin (AO, 3) plus a fixed concentration of Vemurafenib (0,66 ⁇ ) (V0,6).
  • Surviving cells were counted after 72h incubation using a Cell Counter. Ivermectin, Moxidectin and Abamectin did not potentiate Vemurafenib activity on BRAFV600E mutated cells.
  • Figure 13 Combination of a low dose of Ivermectin with increasing doses of Vemurafenib increases its cytotoxicity to BRAF-wt melanoma cells
  • LB 1319-MEL cells were treated with increasing concentrations of Ivermectin alone (0,37; 1; 3 and 10 ⁇ ), or with increasing concentrations of PLX-4032 alone (0,07; 0,22; 0,66 and 2) or with a fixed concentration of Ivermectin (0,37 ⁇ ) plus increasing concentrations of PLX4032 (0,07; 0,22; 0,66 and 2).
  • cell number was quantified using a Cellomics Arrayscan microscope. Number of cells in the untreated condition was used to normalize results.
  • Figure 14 Combination of a low dose of Ivermectin with increasing doses of Vemurafenib increases its cytotoxicity to BRAF-wt melanoma cells Pictures were taken on a Cellomics Arrayscan microscope (20X objective) during the experiment presented in Figure 13.
  • Dabrafenib increases its cytotoxicity to melanoma cells
  • FIG. 18 Combination of a low dose of Ivermectin with increasing doses of Dabrafenib increases its cytotoxicity to melanoma cells Effect of Ivermectin alone, Dabrafenib alone or Ivermectin plus Dabrafenib combination on the survival of BRAFV600E positive melanoma cells.
  • WM266-4 cells were treated with increasing concentrations of Ivermectin alone (0,37; 1; 3 and 10 ⁇ ), or with increasing concentrations of Dabrafenib alone (0,03; 0,09; 0,27 and 0,8) or with a fixed concentration of Ivermectin (0,37 ⁇ ) plus increasing concentrations of Dabrafenib (0,03; 0,09; 0,27 and 0,8).
  • Surviving cells were counted after 72h incubation using a Cellulomics Arrayscan microscope.
  • FIG 19 Ivermectin potentiates Dabrafenib cytotoxicity on melanoma cells Ivermectin potentiates Dabrafenib activity on BRAFV600E mutated cells.
  • WM266-4 cells were treated with Dabrafenib alone or in combination with Ivermectin. The cells were treated with Dabrafenib (0,27 or 0,8 ⁇ ) (D0,27 or D0,8) alone or with 0,37 ⁇ of Ivermectin (10,37). Surviving cells were counted after 72h incubation using a Cell Counter.
  • Figure 20 Anti-PAKl cytotoxicity against melanoma cells
  • LB39-MEL were seeded at lxl0 3 /well and treated with vehicle alone (RPMI/DMSO 0,5%) or with IPA-3 at 5 ⁇ for 72h. Number of cells after treatment was quantified using a Cellomics Arrayscan microscope.
  • Figure 21 Cytotoxicity against melanoma cells of another anti-PAKl (FRAX 597)
  • FRAX 597 a small molecule pyridopyrimidinone, which is a potent inhibitor of the group I PAKs
  • FRAX 597 a small molecule pyridopyrimidinone, which is a potent inhibitor of the group I PAKs
  • PAK1 is the molecular target of Ivermectin involved in its cytotoxicity to melanoma cells.
  • mice Six- to eight-wk-old female NMRI nu/nu (Nude) mice (JANVIER Labs) and C57BL/6 IFN- ⁇ KO mice produced in our animal facility (agreement n°B.31.555.26) were used for in vivo experiments. These immunodepressed mice were used to limit the in vivo immune response against melanoma cells. All experiments involving mice were done using appropriate conditions of husbandry, experimentation and care, supervised by the Ethic Comity of the Institut Claudius Regaud, under the control of the Regional Comity of Midi-Pyrenees (France). Our protocol was validated and received the agreement numbers ICR-2009-0011 and ICR- 2009-0020. Cell lines
  • One murine melanoma cells B 16F 10 wild type NRAS and BRAF
  • two human melanoma cells: WM266-4 wild type NRAS and mutated BRAFV600E
  • A375 wild type NRAS and mutated BRAFV600E
  • All tumor cells were maintained in culture by serial passages in culture medium composed of RPMI 1640 medium supplemented with 10% fetal bovine serum (FCS), ImM glutamine, 1% penicillin-streptomycin-amphotericin B. They were monthly tested to be mycoplasm-free.
  • FCS fetal bovine serum
  • FCS fetal bovine serum
  • ImM glutamine fetal bovine serum
  • penicillin-streptomycin-amphotericin B 1% penicillin-streptomycin-amphotericin B. They were monthly tested to be mycoplasm-free.
  • Thymuses were harvested from four-wk-old female C57BL/6 IFN- ⁇ KO mice, minced and single-cell suspensions of thymocytes were prepared.
  • melanoma cell lines Ten human melanoma cell lines, one murine melanoma cell line and normal murine thymocytes were treated in vitro with Ivermectin at different doses from 0,5 to 25 ⁇ for 72h.
  • Thymocytes were plated at 1 or 2 x 10 6 /well in 24 well plates. Melanoma cells were trypsinized, washed once and plated in culture in 24 well plates. 1,5 mL/well of RPMI 1640 medium supplemented with 10% fetal bovine serum, ImM glutamine, 1% penicillin- streptomycin- amphotericin B (RPMI) was added with vehicle only (RPMI/DMSO 0,25%) or with increasing doses of Ivermectin. Surviving cells were counted 72 hours later using a Cell Counter (Coulter). The number of cells surviving in vehicle alone was used to normalize results. All conditions were done in triplicate and the experiment was repeated twice.
  • RPMI 1640 medium supplemente
  • BRAF-wt or BRAFV600E mutated LB1319-MEL wild type NRAS and BRAF
  • WM266-4 wild type NRAS and mutated BRAFV600E
  • IP intraperitoneal
  • mice Twenty C57BL/6-IFN-y KO mice were injected intravenously (iv) in the tail vein with lxlO 5 B16F10 cells. Two days later and every following day mice were IP injected with 0,lmL of vehicle (PBS/DMSO 0,25%) or 0,1 mL of vehicle containing 3,25 mg/kg of Ivermectin. Mice were sacrificed 10 days later; all mice survived the experiment and did not significantly loose weight. Macroscopic black metastases were detected visually and quantified. These quantifications were done by double blind scoring. The experiment included 10 mice/group.
  • mice Thirteen NMRI-nu/nu mice were injected iv in the tail vein with lxlO 6 WM266-4 cells. Two days later and every following day mice were IP injected with 0,lmL of vehicle (PBS/DMSO 0,25%) or 0,1 ml of vehicle containing 3,25 mg/kg of Ivermectin. Mice were sacrificed 20 days later; all mice survived the experiment and did not loose weight. The lungs were removed, fixed in formalin and paraffin embedded to visualize microscopic metastases. Lung metastases were quantified after immunohistochemical (IHC) staining by a pathologist and a biologist. These analyses were done in double blind.
  • IHC immunohistochemical
  • the IHC staining was done with KB A.62 mAb ready to use from DAKO revealed by FLEX/HRP (20 min incubation) then by FLEX DAB+ Sub-Chromo (10 min incubation) and FLEX Hematoxylin (5 min incubation). The experiment included 6 or 7 mice/group.
  • WM266-4 and LB1319-MEL cells were plated at 5 x 10 3 per well in 96 well plates.
  • Treatments were realized using a two-entry matrix with concentrations of Vemurafenib ranging from 2 ⁇ to 0,0625 ⁇ by two-fold serial dilutions (lines contained Vemurafenib dose response).
  • Ivermectin starting concentration was fixed to 10 ⁇ and decreased to 0,315 ⁇ by two fold dilutions (columns contained Ivermectin dose response).
  • 72h post treatment cells were washed with PBS and incubated with RPMI medium containing Hoechst 33342, to measure nucleus number, surface and intensity. Cells were scored on a Cellomics Arrayscan Vti automated fluorescence microscope using the cell cycle algorithm.
  • LB1319-MEL and WM266-4 cells were treated in vitro for 72h with Ivermectin alone (at 0,37; 1 ; 3 and 10 ⁇ ) or with Vemurafenib (PLX4032) alone (at 0,07; 0,22; 0,66 and 2 ⁇ ) or with combinations of fixed concentrations of Ivermectin (0,37 or ⁇ ) with increasing concentrations of Vemurafenib.
  • Surviving cells were counted 72 hours later using a Cell Counter (Coulter).
  • WM266-4 cells were treated in vitro for 72h with Ivermectin alone (at 0,37; 1; 3 and 10 ⁇ ) or with Dabrafenib alone (at 0,01; 0,03; 0,09; 0,27 and 0,8 ⁇ ) or with combinations of a fixed concentration of Ivermectin (0,37 ⁇ ) with increasing concentrations of Dabrafenib.
  • Surviving cells were counted 72 h later using a Cell Counter (Coulter) or a Cellomics Arrayscan Vti automated fluorescence microscope.
  • LB39-MEL human metastatic melanoma cells
  • MRC5 normal human fibroblasts
  • Ivermectin which has an IC50 of less than 5 ⁇ and which has a differential toxicity on LB39-MEL versus MRC5 cells ( Figure 1 and illustrated in Figure 2).
  • Ivermectin (trade name: Stromectol), a FDA approved molecule that is already used for its anti helminthic capacities.
  • Ivermectin is specifically toxic to melanoma cells
  • Ivermectin is cytotoxic to melanoma cells independently of BRAF status, as cells that do not carry BRAF V600E mutation and mutated cells are killed by Ivermectin.
  • Ivermectin is not toxic in vivo
  • Ivermectin could be used in preclinical phases for the treatment of metastatic melanoma.
  • the molecule was daily administered by intraperitoneal (IP) injections in C57Bl/6-IFNy-KO and NMRI- nu/nu mice.
  • mice Twenty two C57B1/6 IFNy-KO mice were weighed before and after the daily and repeated IP injections (7 days) with vehicle (PBS/DMSO 0,25%>) or with Ivermectin at 3,25 mg/kg. Before injections, the average weight of mice was 18,2 grams, after the vehicle (PBS/DMSO 0,25%>) injections the average weight was 18,3 g and after Ivermectin injections at 3,25 mg/kg the average weight was 16,7 g. These results show that weight loss (8.8%) induced by Ivermectin injections in C57Bl/6-IFNy-KO mice is less than 10% and therefore acceptable (Figure 4).
  • mice were weighed before and after the daily and repeated IP injections (20 days) with vehicle (PBS/DMSO 0,25%) or with Ivermectin at 3,25 mg/kg. Before injections the average weight of mice was 25,8 grams. After vehicle injections the average weight was 27,7 grams and after Ivermectin injections the average weight was 26,7 grams.
  • Ivermectin decreases metastases implantation in mice
  • mice were left untreated for 48 hours, in order to allow the B16F10 melanoma cells to perform the early stages of metastasis (extravasation and implantation) into the lungs. Then the mice were injected intraperitoneally (IP) lx/day for 7 days with 3.25mg/kg of Ivermectin. Control mice similarly injected with B16F10 cells were only treated with vehicle solution (PBS/DMSO 0.25%). The mice were sacrificed ten days after the injections of B16F10 cells, their lungs were removed and the number of metastasis counted in double blind experiments.
  • IP intraperitoneally
  • mice were used NMRI nu/nu mice in which we injected iv WM266-4 cells (lxlO 6 cells/mouse). These mice are immunodepressed and human WM266-4 melanoma cells injected into their tail vein produce lung metastases. After WM266-4 iv injections, mice were left untreated for 48 hours in order to allow these tumor cells to perform the early stages of metastasis into the lungs. The mice were then injected intraperitoneally (IP) lx/day for 17 days with 3,25mg/kg of Ivermectin or with vehicle (PBS/DMSO 0,25%) alone.
  • IP intraperitoneally
  • the experiment is longer because human melanomas have a longer time of implantation and multiplication in nude mice than B16F10 cells injected in syngeneic C57BL/6 mice.
  • Mice were sacrificed twenty days after the injections of WM266-4, their lungs were removed and the number of metastasis was quantified after immunohistochemical staining with KB A.62 mAb.
  • This anti-melanoma antibody is used in diagnosis of primary and metastatic melanomas but also to detect micro- metastases in sentinel lymph node. The results show that Ivermectin is very efficient to decrease the occurrence of lung metastases.
  • the anti-melanoma specific activity of Ivermectin and four other mectins were compared in vitro on LB1319-MEL (BRAF-wt) and WM266-4 (BRAFV600E mutated) melanoma cells.
  • WM266-4 cells were also treated with Ivermectin and the four other mectins and analyzed as previously.
  • the results obtained with this BRAFV600E mutated melanoma cell line show that Ivermectin and all the other mectins are effective to kill melanoma cells bearing the BRAF V600E mutation.
  • the Moxidectin is the most efficient molecule with an IC50 of 2,5 ⁇ versus 4 or 5 ⁇ for the other molecules (Figure 9). Moxidectin has the highest activity and the simplest chemical structure. Therefore it potentially represents the minimal structure required for anti melanoma activity of these macrocyclic lactones, but deep structure relationship determination will be required to confirm this hypothesis.
  • Vemurafenib (PLX-4032) is a pharmacological molecule designed to inhibit the constitutive activation of the BRAFV600E mutated protein involved in melanoma metastasis. It has a therapeutic effect only in patients with metastatic melanomas bearing this mutation, and its effect is often temporary.
  • WM266-4 cells were treated with increasing concentrations of Vemurafenib alone (from 0,0625 to 2 ⁇ ), or with increasing concentrations of Ivermectin alone (from 0,315 to 10 ⁇ ) or with increasing combinations of both molecules.
  • An illustration is presented in Figure 10 showing no increase in cytotoxicity induced by a 72h treatment with a combination of a fixed concentration at 0,315 ⁇ of Ivermectin, which does not induce tumor cells death, associated with increasing concentrations of Vemurafenib (from 0,0625 to 2 ⁇ ).
  • the number of WM266- 4 cells was quantified using a Cellomics ArrayScan microscope.
  • WM266-4 cells were also treated with increasing concentrations of Vemurafenib alone
  • Ivermectin alone is capable of killing these melanoma cells in a dose dependent manner (as also previously shown in Figure 3).
  • Ivermectin potentiates the action of Vemurafenib on melanoma cells that do not carry the BRAFV600E mutation ( Figures 13, 14 and 15).
  • Figure 14 are presented pictures showing sensitization to lysis by Vemurafenib induced by a low dose of Ivermectin (0,3 ⁇ ) on LB 1319-MEL. This sensitization to Vemurafenib cytotoxicity is also observed with surviving LB 1319-MEL cells counted after 72h incubation using a Cell Counter ( Figure 15). These melanoma cells were treated with Ivermectin alone (0,3, 1, 3 or 10 ⁇ ) or with Vemurafenib alone (0,07, 0,22, 0,66, 1 ⁇ ) or with two combinations of low doses of Ivermectin (1 and 0,3 ⁇ ) with the increasing concentrations of Vemurafenib.
  • LB 1319-MEL cells were treated with Vemurafenib alone (0,66 ⁇ ) or with combinations of a low dose of the macrocyclic lactone (0,3 ⁇ ) with 0,66 ⁇ of Vemurafenib.
  • Ivermectin these two other mectins potentiated the Vemurafenib-induced killing of these BRAF-wt melanoma cells ( Figure 16).
  • Dabrafenib like Vemurafenib, is a promising pharmacological molecule inhibiting the constitutive activation of the BRAFV600E mutated protein and having a therapeutic effect in patients with metastatic melanomas bearing this mutation.
  • Ivermectin was tested the capacity of Ivermectin to potentiate the anti melanoma activity of Dabrafenib on human melanoma cells.
  • WM266-4 melanoma cells carrying the BRAF-V600E mutation were treated in vitro for 72 hours with increasing doses of Dabrafenib and Ivermectin, alone or in combination.
  • WM266-4 cells were treated with concentrations of Dabrafenib alone (from 0,01 to 0,8 ⁇ ) or with concentrations of Ivermectin alone (from 0,37 to 10 ⁇ ) or with combinations of both molecules: a fixed concentration at 0,37 ⁇ of Ivermectin, which does not induce tumor cells death, associated with increasing concentrations of Dabrafenib (from 0,01 to 0,8 ⁇ ).
  • the number of WM266-4 cells was quantified using a Cellomics ArrayScan microscope. The results show that the combination Ivermectin plus Dabrafenib is more cytotoxic to mutated melanoma cells than Dabrafenib alone.
  • WM266-4 cells were also treated with two concentrations of Dabrafenib alone (0,27 and 0,8 ⁇ ) or with two combinations of a fixed concentration at 0,37 ⁇ of Ivermectin, which does not induce tumor cells death, associated with Dabrafenib at 0,27 and 0,8 ⁇ . After 72h incubation, the number of WM266-4 cells was quantified using a Cell Counter. The results confirmed that the combination Ivermectin plus Dabrafenib is more cytotoxic to melanoma cells than Dabrafenib alone ( Figures 19).
  • PAK1 Serine/threonine p21 -activated protein kinase 1
  • PAK proteins a family of serine/threonine p21 -activated kinases, include PAK1 , PAK2, PAK3 and PAK4. They are critical effectors that link the Rho-Rac-Cdc42 GTPases to cytoskeleton reorganization and nuclear signaling and have been implicated in a wide range of biological activities. PAK1 is a key player in several pathways, whose perturbation is known to be oncogenic. Among others functions PAK1 regulates cell motility and morphology.
  • PAK1 being Ivermectin target in melanoma cytotoxicity is due to the fact that Ivermectin inactivates PAK1, which inhibits the phosphorylation of the kinase RAF-1 (CRAF) at Ser338 (p-Rafl) and consequently MAPK cascade.
  • MAPK pathway is involved in cancer induction, maintenance and progression.
  • RAF proteins interact, including BRAF activates CRAF, and both proteins can activate MEK (J. Downward et al. Nature Med 2011, vol 17, p 286-288). So, in melanomas, the inhibition of RAF 1 phosphorylation by Ivermectin, via PAK1, could inhibit MEK activation and consequently tumor development.
  • PAK1 is the Ivermectin target involved in melanoma treatment sensitivity.
  • Ivermectin and other PAK1 inhibitors appear extremely promising against metastatic melanoma since their effects are independent of the presence of the BRAF V600E mutation. Indeed, among the melanoma lines we tested, LB33-MEL, LB1319-MEL, MZ2-MEL.3 and B16F10, among others, do not carry the BRAF mutation. Ivermectin and several macrocyclic lactones variants have the capacity to kill all the melanoma cells, including the BRAFV600E negative cells. Moreover Ivermectin and these macrocyclic lactones have a second particularly interesting property.
  • Ivermectin or other mectins
  • Ivermectin concentrations used in our tests are similar to those used for its normal FDA approved anti helmintic use, this molecule should directly enter into a Phase I/II Fast Track Clinical Trial. If its combination with anti MAPK pathway products is proven to be efficient in patients, Ivermectin would provide an asset to current treatments and would potentiate their action. Ivermectin could become the reference molecule for treatment of metastatic melanoma not carrying BRAF V600E mutation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pharmaceutiques pour le traitement du mélanome.
PCT/EP2016/054615 2015-03-05 2016-03-04 Méthodes et compositions pharmaceutiques destinées au traitement du mélanome Ceased WO2016139331A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305339.2 2015-03-05
EP15305339 2015-03-05

Publications (1)

Publication Number Publication Date
WO2016139331A1 true WO2016139331A1 (fr) 2016-09-09

Family

ID=52737027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/054615 Ceased WO2016139331A1 (fr) 2015-03-05 2016-03-04 Méthodes et compositions pharmaceutiques destinées au traitement du mélanome

Country Status (1)

Country Link
WO (1) WO2016139331A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2021150543A1 (fr) * 2020-01-20 2021-07-29 Texas Tech University System Inhibiteur de jak/stat, nouveau et puissant

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3503994A (en) 1966-06-29 1970-03-31 Commercial Solvents Corp Macrocyclic lactones
WO1993016189A1 (fr) 1992-02-17 1993-08-19 Pfizer Inc. Nouvelles lactones macrocycliques et une des souches productives s'y rapportant
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
WO2011075592A1 (fr) 2009-12-17 2011-06-23 Merial Limited Compositions contenant des composés de lactone macrocyclique et des spiro-dioxépino-indoles
WO2012028556A1 (fr) 2010-08-31 2012-03-08 Bayer Animal Health Gmbh Lactones macrocycliques et leur utilisation et leurs combinaisons avec d'autres substances actives
WO2012078605A1 (fr) 2010-12-07 2012-06-14 Merial Limited Formulations de combinaison topiques de lactones macrocycliques avec des pyréthroïdes synthétiques
WO2012150543A1 (fr) 2011-05-02 2012-11-08 Universite De Geneve Lactones macrocycliques et leur utilisation
WO2013135745A1 (fr) * 2012-03-16 2013-09-19 F. Hoffmann-La Roche Ag Procédés de traitement d'un mélanome avec des inhibiteurs de pak1

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3503994A (en) 1966-06-29 1970-03-31 Commercial Solvents Corp Macrocyclic lactones
WO1993016189A1 (fr) 1992-02-17 1993-08-19 Pfizer Inc. Nouvelles lactones macrocycliques et une des souches productives s'y rapportant
WO1999032619A1 (fr) 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6573099B2 (en) 1998-03-20 2003-06-03 Benitec Australia, Ltd. Genetic constructs for delaying or repressing the expression of a target gene
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
WO2001036646A1 (fr) 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibition d"expression genique a l"aide d"arn bicatenaire
WO2001068836A2 (fr) 2000-03-16 2001-09-20 Genetica, Inc. Procedes et compositions d'interference d'arn
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
WO2011075592A1 (fr) 2009-12-17 2011-06-23 Merial Limited Compositions contenant des composés de lactone macrocyclique et des spiro-dioxépino-indoles
WO2012028556A1 (fr) 2010-08-31 2012-03-08 Bayer Animal Health Gmbh Lactones macrocycliques et leur utilisation et leurs combinaisons avec d'autres substances actives
WO2012078605A1 (fr) 2010-12-07 2012-06-14 Merial Limited Formulations de combinaison topiques de lactones macrocycliques avec des pyréthroïdes synthétiques
WO2012150543A1 (fr) 2011-05-02 2012-11-08 Universite De Geneve Lactones macrocycliques et leur utilisation
WO2013135745A1 (fr) * 2012-03-16 2013-09-19 F. Hoffmann-La Roche Ag Procédés de traitement d'un mélanome avec des inhibiteurs de pak1

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
AGNEW CHEM INTL. ED. ENGL, vol. 33, 1994, pages 183 - 186
C GLITZA; M A DAVIES, CHIN CLIN ONCOL., vol. 3, 2014, pages 27
DE BENEDETTI ET AL., J IMMUNOL, vol. 166, 2001, pages 4334 - 4340
DOSSETT LA; KUDCHADKAR RR; ZAGER JS: "BRAF and MEK inhibition in melanoma", EXPERT OPIN DRUG SAF., 4 February 2015 (2015-02-04), pages 1 - 12
DRINYAEV V A ET AL: "Antitumor effect of avermectins", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 19 - 23, XP004587589, ISSN: 0014-2999, DOI: 10.1016/J.EJPHAR.2004.08.009 *
FRANCESCO SPAGNOLO; PAOLA GHIORZO; PAOLA QUEIROLO: "Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma", ONCOTARGET, vol. 5, no. 21, 2014, pages 102 - 21
GLITZA I C; DAVIES M A: "Genotyping of cutaneous melanoma", CHIN CLIN ONCOL., vol. 3, 2014, pages 27
HASHIMOTO H ET AL: "Ivermectin inactivates the kinase PAK1 and blocks the PAK1 dependent growth of human ovarian cancer and NF2 tumor cell lines", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, ELSEVIER, AMSTERDAM, NL, vol. 3, no. 6, 1 December 2009 (2009-12-01), pages 243 - 246, XP002700324, ISSN: 1740-6773 *
HISASHI HASHIMOTO ET AL., DRUG DISCOV THER., vol. 3, no. 6, 2009, pages 243 - 246
HOLDERFIELD M. ET AL.: "Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond", NATURE REVIEWS CANCER, vol. 14, 2014, pages 455 - 467
ILIEVA KM ET AL.: "Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma", MOL CANCER THER, vol. 13, no. 12, December 2014 (2014-12-01), pages 2769 - 83
ILIEVA KM ET AL.: "Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma", MOL CANCER THER., vol. 13, no. 12, December 2014 (2014-12-01), pages 2769 - 83
J. DOWNWARD ET AL., NATURE MED, vol. 17, 2011, pages 286 - 288
KRIEGLER: "A Laboratory Manual", 1990, W.H. FREEMAN C.O.
LEONARD ET AL., CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 53Z7 - 5334
LESPINE A.: "Lipid-like properties and pharmacology of the anthelmintic macrocyclic lactones", EXPERT OPIN DRUG METAB TOXICOL., vol. 9, no. 12, December 2013 (2013-12-01), pages 1581 - 95
LESPINE A: "Lipid-like properties and pharmacology of the anthelmintic macrocyclic lactones", EXPERT OPIN DRUG METAB TOXICOL., vol. 9, no. 12, December 2013 (2013-12-01), pages 1581 - 95
LONG GV. ET AL.: "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma", N ENGL J MED., vol. 371, no. 20, 13 November 2014 (2014-11-13), pages 1877 - 88
M. HOLDERFIELD ET AL., NATURE REVIEWS CANCER, vol. 14, 2014, pages 455 - 467
MEHNERT JM; KLUGER HM, CURR ONCOL REP., vol. 14, 2012, pages 449 - 457
MEHNERT JM; KLUGER HM: "Driver mutations in melanoma: lessons learned from bench-to-bedside studies", CURR ONCOL REP., vol. 14, 2012, pages 449 - 457
MURRY: "Methods in Molecular Biology", vol. 7, 1991, HUMANA PRESS, INC.
NICHOLAS P. RESTIFO; MARK E. DUDLEY; STEVEN A. ROSENBERG: "Adoptive immunotherapy for cancer: harnessing the T cell response", NATURE REVIEWS IMMUNOLOGY, vol. 12, April 2012 (2012-04-01)
PAOLA GHIORZO AND PAOLA QUEIROLO, ONCOTARGET, vol. 5, no. 21, 2014, pages 102 - 21
ROULSTONE V. ET AL.: "BRAF- and MEK-targeted Small Molecule Inhibitors Exert Enhanced Anti-Melanoma Effects in Combination with Oncolytic Reovirus through ER Stress", MOL THER, 26 January 2015 (2015-01-26)
ROULSTONE V. ET AL.: "BRAF- and MEK-targeted Small Molecule Inhibitors Exert Enhanced Anti-Melanoma Effects in Combination with Oncolytic Reovirus through ER Stress", MOL THER., 26 January 2015 (2015-01-26)
SANBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
SUZUKI ET AL., EUROP J OF IMMUNOL, vol. 22, no. 8, 1992, pages 1989 - 1993

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2021150543A1 (fr) * 2020-01-20 2021-07-29 Texas Tech University System Inhibiteur de jak/stat, nouveau et puissant

Similar Documents

Publication Publication Date Title
US12234480B2 (en) Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells
WO2018185516A1 (fr) Méthodes et compositions pharmaceutiques destinées à traiter une toxicité cardiovasculaire induite par une thérapie anticancéreuse
WO2019106126A1 (fr) Modulateurs mdm2 pour le diagnostic et le traitement du liposarcome
US12599662B2 (en) Methods and compositions for treating cancers
US20190345500A1 (en) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
WO2016139331A1 (fr) Méthodes et compositions pharmaceutiques destinées au traitement du mélanome
EP3810200B1 (fr) Compositions permettant de traiter le mélanome
US20240122938A1 (en) Methods and compositions for treating uveal melanoma
Mertens et al. Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice
US20250041261A1 (en) Methods and compositions for treating melanoma
US20240165094A1 (en) Methods and compositions for treating melanoma
WO2017144546A1 (fr) Méthodes et compositions pharmaceutiques pour le traitement d'un carcinome de rhinopharyngite
HK40100442A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor
US20210100859A1 (en) Herpes simplex virus (hsv) anticancer therapies
WO2024161015A1 (fr) Méthode de traitement de maladies liées à l'âge
WO2025228998A1 (fr) Utilisation d'inhibiteurs de hdac4 pour le traitement de mélanome
WO2026093364A1 (fr) Activateur de pik3ca permettant de stimuler la formation du follicule pileux et le cyclage
WO2025210123A1 (fr) Procédés et composition pharmaceutique pour le traitement de cancers
WO2025132479A1 (fr) Inhibiteur de flt3 pour moduler la polarisation de macrophages
HK40023269A (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
WO2025219330A1 (fr) Détection de ppix pour utilisation dans des méthodes de prédiction de la sensibilité à la ferroptose du mélanome et de la résistance aux thérapies ciblées
WO2022109227A1 (fr) Polythérapie anticancéreuse par inhibiteurs de point de contrôle immunitaire b7-h3 et cd47 et ses méthodes d'utilisation
HK40023269B (en) Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd
HK1256917B (en) Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16707803

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16707803

Country of ref document: EP

Kind code of ref document: A1